Cardiology in Review · Nov 12, 2026

Efficacy and Safety of the Oral PCSK9 Inhibitor Enlicitide in Adults With Dyslipidemia: A GRADE-Assessed Meta-Analysis of Randomized Controlled Trials With Dose–Response Meta-Regression

By Talkhan A, Abou Elezz AM, Kanaan D et al.

Many patients do not reach low-density lipoprotein cholesterol (LDL-C) goals with statins, and the use of injectable proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors is limited by the route of administration and cost. Enlicitide (MK-0616) is an oral macrocyclic peptide that inhibits PCSK9. We searched PubMed, Scopus, Web of Science, and the Cochrane Library through September 24, 2026, for randomized controlled trials comparing enlicitide with placebo in adults with dyslipidemia, pooled data with random-effects models, and performed dose–response meta-regression and Grading of Recommendations, Assessment, Development and Evaluations assessment. Three double-blind trials (3588 participants) were included. Enlicitide reduced LDL-C by 56.81 percentage points relative to placebo [95% confidence interval (CI), −62.19 to −51.44; high certainty] and increased attainment of LDL-C goals [risk ratio (RR), 27.82; 95% CI, 7.22–107.19]. It also reduced nonhigh-density lipoprotein cholesterol (−51.96 percentage points), apolipoprotein B (−47.53), and lipoprotein(a) (−24.86), whereas high-density lipoprotein cholesterol did not change significantly. Higher doses were associated with greater LDL-C reductions. Any adverse events (RR, 1.03; 95% CI, 0.98–1.09), serious adverse events (0.84; 0.68–1.04), discontinuations due to adverse events (0.76; 0.52–1.11), and deaths (0.95; 0.41–2.21) did not differ from placebo. Oral enlicitide produces LDL-C lowering of a magnitude similar to that of injectable PCSK9 antibodies, with a short-term safety profile comparable to placebo; its effect on cardiovascular events remains to be established.

doi.org/10.1097/crd.0000000000001537PubMed 43038165Interventions

AgingResearch.News